{
    "nctId": "NCT02027818",
    "briefTitle": "Study of the ICG Distribution in the Margins of Breast Cancer After Tumorectomy",
    "officialTitle": "Study of the (Intravenously Injected) Indocyanine Green Distribution in the Margins of Breast Cancer After Tumorectomy",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 20,
    "primaryOutcomeMeasure": "- Evaluation of the ability of NIR imaging to show (fluorescent) the tumoral volumes, the tumoral tissues to be analyzed by the pathologist, especially at the level of the operative margins",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with histopathological diagnosis of mammary cancer who are candidate for tumorectomy, either with SLN selective lymphadenectomy, or with complete axillary node dissection,\n* Informed consent form signed.\n\nExclusion Criteria:\n\n* Diagnosis of mammary cancer established by \"gross\" biopsy,\n* Age less than18 years old.\n* Inability to give informed consent.\n* History of allergy or hypersensitivity against the investigational product (its active substance or ingredients), to iodine or to shellfish.\n* Apparent hyperthyroidism, autonomous thyroid adenoma, unifocal, multifocal or disseminated autonomies of the thyroid gland.\n* Documented coronary disease.\n* Advanced renal impairment (creatinine \\> 1,5mg/dl).\n* During the 2 weeks before the enrolment, concurrent medication which reduces or increases the extinction of ICG (i.e. anticonvulsants, haloperidol and Heparin).\n* Pregnancy, breastfeeding",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}